Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>Seasonal malaria chemoprevention (SMC), with regular use of amodiaquine plus sulfadoxine-pyrimethamine (AQ/SP) during the transmission season, is now a standard malaria control measure in the Sahel subregion of Africa. Another strategy under study is SMC with dihydroartemisinin plus piperaquine (DP).<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Plasmodium falciparum</jats:named-content>single nucleotide polymorphisms (SNPs) in<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">P. falciparum</jats:named-content><jats:italic>crt</jats:italic>(<jats:italic>pfcrt</jats:italic>),<jats:italic>pfmdr1</jats:italic>,<jats:italic>pfdhfr</jats:italic>, and<jats:italic>pfdhps</jats:italic>are associated with decreased response to aminoquinoline and antifolate antimalarials and are selected by use of these drugs. To characterize selection by SMC of key polymorphisms, we assessed 13 SNPs in<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">P. falciparum</jats:named-content>isolated from children aged 3 to 59 months living in southwestern Burkina Faso and randomized to receive monthly DP or AQ/SP for 3 months in 2009. We compared SNP prevalence before the onset of SMC and 1 month after the third treatment in<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">P. falciparum</jats:named-content>PCR-positive samples from 120 randomly selected children from each treatment arm and an additional 120 randomly selected children from a control group that did not receive SMC. The prevalence of relevant mutations was increased after SMC with AQ/SP. Significant selection was seen for<jats:italic>pfcrt</jats:italic>76T (68.5% to 83.0%,<jats:italic>P</jats:italic>= 0.04),<jats:italic>pfdhfr</jats:italic>59R (54.8% to 83.3%,<jats:italic>P</jats:italic>= 0.0002), and<jats:italic>pfdhfr</jats:italic>108N (55.0% to 87.2%,<jats:italic>P</jats:italic>= 0.0001), with trends toward selection of<jats:italic>pfmdr1</jats:italic>86Y,<jats:italic>pfdhfr</jats:italic>51I, and<jats:italic>pfdhps</jats:italic>437G. After SMC with DP, only borderline selection of wild-type<jats:italic>pfmdr1</jats:italic>D1246 (mutant; 7.7% to 0%,<jats:italic>P</jats:italic>= 0.05) was seen. In contrast to AQ/SP, SMC with DP did not clearly select for known resistance-mediating polymorphisms. SMC with AQ/SP, but not DP, may hasten the development of resistance to components of this regimen. (This study has been registered at ClinicalTrials.gov under registration no. NCT00941785.)</jats:p>

Original publication

DOI

10.1128/aac.02406-14

Type

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

07/2014

Volume

58

Pages

3660 - 3665